Kazuki Nozawa, Medical Oncologist at Nagoya City University, shared on X:
“I’ve been waiting for this!
Palbociclib has been approved for hormone receptor-positive HER2-positive metastatic recurrent breast cancer based on the PATINA trial! Even though Japan did not participate in the PATINA trial, this expanded indication feels like a turning point.
There’s no doubt that more options are definitely good news. Toshimi Takan, Professor’s comment too.”
You can also read ‘FDA Approves Palbociclib-Based Maintenance Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer‘
